StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) changes point to an 'extended period of underperformance' - SVB Securities
February 24, 2023 10:16 AM
Moderna (NASDAQ: MRNA) was cut to Underperform from Market Perform by SVB Securities analyst Mani Foroohar on Friday.Foroohar also lowered ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Downgrades
Hot List
Next Articles
Moderna (MRNA) PT Lowered to $185 at Morgan Stanley
February 24, 2023 8:10 AM
Moderna (MRNA) PT Lowered to $127 at JPMorgan
February 24, 2023 7:15 AM
SVB Leerink Downgrades Moderna (MRNA) to Underperform
February 24, 2023 6:06 AM
Moderna (MRNA) PT Lowered to $185 at Morgan Stanley Following EPS
February 23, 2023 12:39 PM
Moderna (MRNA) PT Lowered to $214 at Piper Sandler
February 23, 2023 12:13 PM
Moderna falls as waning demand for COVID-19 vaccines hit sales, profit
February 23, 2023 9:06 AM
Moderna forecasts COVID sales decline as costs rise, shares fall
February 23, 2023 7:53 AM
Moderna (MRNA) Q4 Revenue Tops Consensus
February 23, 2023 7:05 AM
